nodes	percent_of_prediction	percent_of_DWPC	metapath
Mitoxantrone—Topoisomerase Inhibitors—Etoposide—muscle cancer	0.298	0.611	CiPCiCtD
Mitoxantrone—Topoisomerase Inhibitors—Doxorubicin—muscle cancer	0.19	0.389	CiPCiCtD
Mitoxantrone—hematologic cancer—muscle cancer	0.186	0.659	CtDrD
Mitoxantrone—sarcoma—muscle cancer	0.0963	0.341	CtDrD
Mitoxantrone—TOP2A—Etoposide—muscle cancer	0.0203	0.114	CbGbCtD
Mitoxantrone—ABCC1—Dactinomycin—muscle cancer	0.0199	0.112	CbGbCtD
Mitoxantrone—TOP2A—Doxorubicin—muscle cancer	0.0138	0.0779	CbGbCtD
Mitoxantrone—ABCG2—Dactinomycin—muscle cancer	0.0133	0.0751	CbGbCtD
Mitoxantrone—ABCC1—Vincristine—muscle cancer	0.0122	0.0691	CbGbCtD
Mitoxantrone—ABCC1—Etoposide—muscle cancer	0.0112	0.0633	CbGbCtD
Mitoxantrone—CYP2E1—Dacarbazine—muscle cancer	0.0109	0.0617	CbGbCtD
Mitoxantrone—CYP1B1—Doxorubicin—muscle cancer	0.0108	0.0608	CbGbCtD
Mitoxantrone—ABCG2—Vincristine—muscle cancer	0.0082	0.0462	CbGbCtD
Mitoxantrone—ABCC1—Doxorubicin—muscle cancer	0.00766	0.0432	CbGbCtD
Mitoxantrone—ABCG2—Etoposide—muscle cancer	0.00751	0.0424	CbGbCtD
Mitoxantrone—ABCC1—Methotrexate—muscle cancer	0.00742	0.0418	CbGbCtD
Mitoxantrone—CYP2E1—Etoposide—muscle cancer	0.00536	0.0302	CbGbCtD
Mitoxantrone—ABCG2—Doxorubicin—muscle cancer	0.00512	0.0289	CbGbCtD
Mitoxantrone—ABCG2—Methotrexate—muscle cancer	0.00496	0.028	CbGbCtD
Mitoxantrone—ABCB1—Dactinomycin—muscle cancer	0.0048	0.0271	CbGbCtD
Mitoxantrone—ABCB1—Vincristine—muscle cancer	0.00296	0.0167	CbGbCtD
Mitoxantrone—ABCB1—Etoposide—muscle cancer	0.00271	0.0153	CbGbCtD
Mitoxantrone—ABCB1—Doxorubicin—muscle cancer	0.00185	0.0104	CbGbCtD
Mitoxantrone—ABCB1—Methotrexate—muscle cancer	0.00179	0.0101	CbGbCtD
Mitoxantrone—CYP3A4—Vincristine—muscle cancer	0.00177	0.00999	CbGbCtD
Mitoxantrone—CYP3A4—Etoposide—muscle cancer	0.00162	0.00915	CbGbCtD
Mitoxantrone—PIM1—Validated targets of C-MYC transcriptional activation—PTMA—muscle cancer	0.00136	0.167	CbGpPWpGaD
Mitoxantrone—CYP3A4—Doxorubicin—muscle cancer	0.00111	0.00624	CbGbCtD
Mitoxantrone—PIM1—C-MYB transcription factor network—MYF6—muscle cancer	0.00098	0.121	CbGpPWpGaD
Mitoxantrone—SLC47A2—renal system—muscle cancer	0.000706	0.0681	CbGeAlD
Mitoxantrone—SLC47A2—tendon—muscle cancer	0.000551	0.0531	CbGeAlD
Mitoxantrone—SLC47A2—vagina—muscle cancer	0.000512	0.0493	CbGeAlD
Mitoxantrone—PIM1—Ectoderm Differentiation—PAX3—muscle cancer	0.000476	0.0586	CbGpPWpGaD
Mitoxantrone—SLC47A2—head—muscle cancer	0.000473	0.0456	CbGeAlD
Mitoxantrone—PIM1—renal system—muscle cancer	0.000461	0.0445	CbGeAlD
Mitoxantrone—BTK—tendon—muscle cancer	0.000416	0.0401	CbGeAlD
Mitoxantrone—PIM1—cardiac atrium—muscle cancer	0.000413	0.0398	CbGeAlD
Mitoxantrone—BTK—bone marrow—muscle cancer	0.000403	0.0388	CbGeAlD
Mitoxantrone—PIM1—C-MYB transcription factor network—CD34—muscle cancer	0.00039	0.048	CbGpPWpGaD
Mitoxantrone—PIM1—C-MYB transcription factor network—MYOD1—muscle cancer	0.00039	0.048	CbGpPWpGaD
Mitoxantrone—BTK—vagina—muscle cancer	0.000386	0.0372	CbGeAlD
Mitoxantrone—PIM1—tendon—muscle cancer	0.00036	0.0347	CbGeAlD
Mitoxantrone—PIM1—bone marrow—muscle cancer	0.000349	0.0336	CbGeAlD
Mitoxantrone—BTK—testis—muscle cancer	0.000344	0.0332	CbGeAlD
Mitoxantrone—PIM1—vagina—muscle cancer	0.000334	0.0322	CbGeAlD
Mitoxantrone—PIM1—Validated targets of C-MYC transcriptional activation—HMGA1—muscle cancer	0.000311	0.0382	CbGpPWpGaD
Mitoxantrone—PIM1—head—muscle cancer	0.000309	0.0298	CbGeAlD
Mitoxantrone—PIM1—Ectoderm Differentiation—DMD—muscle cancer	0.000303	0.0372	CbGpPWpGaD
Mitoxantrone—PIM1—testis—muscle cancer	0.000298	0.0287	CbGeAlD
Mitoxantrone—SLC47A1—renal system—muscle cancer	0.000247	0.0238	CbGeAlD
Mitoxantrone—TOP2A—Vindesine—Vincristine—muscle cancer	0.000232	0.236	CbGdCrCtD
Mitoxantrone—PIM1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	0.00023	0.0283	CbGpPWpGaD
Mitoxantrone—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—TP63—muscle cancer	0.00023	0.0283	CbGpPWpGaD
Mitoxantrone—TOP2A—tendon—muscle cancer	0.000211	0.0204	CbGeAlD
Mitoxantrone—TOP2A—bone marrow—muscle cancer	0.000205	0.0197	CbGeAlD
Mitoxantrone—TOP2A—vagina—muscle cancer	0.000196	0.0189	CbGeAlD
Mitoxantrone—SLC47A1—tendon—muscle cancer	0.000193	0.0186	CbGeAlD
Mitoxantrone—CYP1B1—smooth muscle tissue—muscle cancer	0.000188	0.0181	CbGeAlD
Mitoxantrone—CYP1B1—renal system—muscle cancer	0.000181	0.0175	CbGeAlD
Mitoxantrone—SLC47A1—vagina—muscle cancer	0.000179	0.0173	CbGeAlD
Mitoxantrone—TOP2A—testis—muscle cancer	0.000175	0.0169	CbGeAlD
Mitoxantrone—SLC47A1—head—muscle cancer	0.000165	0.0159	CbGeAlD
Mitoxantrone—SLC47A1—testis—muscle cancer	0.00016	0.0154	CbGeAlD
Mitoxantrone—PIM1—C-MYB transcription factor network—KIT—muscle cancer	0.000149	0.0184	CbGpPWpGaD
Mitoxantrone—TOP2A—Vinorelbine—Vincristine—muscle cancer	0.000146	0.149	CbGdCrCtD
Mitoxantrone—TOP2A—Teniposide—Etoposide—muscle cancer	0.000146	0.149	CbGdCrCtD
Mitoxantrone—TOP2A—Podofilox—Etoposide—muscle cancer	0.000146	0.149	CbGdCrCtD
Mitoxantrone—ABCC1—cardiac atrium—muscle cancer	0.000146	0.0141	CbGeAlD
Mitoxantrone—CYP1B1—tendon—muscle cancer	0.000141	0.0136	CbGeAlD
Mitoxantrone—ABCC1—tendon—muscle cancer	0.000127	0.0123	CbGeAlD
Mitoxantrone—CYP1B1—head—muscle cancer	0.000121	0.0117	CbGeAlD
Mitoxantrone—PIM1—C-MYB transcription factor network—CDKN2A—muscle cancer	0.000121	0.0149	CbGpPWpGaD
Mitoxantrone—ABCC1—vagina—muscle cancer	0.000118	0.0114	CbGeAlD
Mitoxantrone—CYP1B1—testis—muscle cancer	0.000117	0.0113	CbGeAlD
Mitoxantrone—CYP2E1—renal system—muscle cancer	0.000117	0.0113	CbGeAlD
Mitoxantrone—PIM1—C-MYB transcription factor network—PTGS2—muscle cancer	0.000113	0.0139	CbGpPWpGaD
Mitoxantrone—CYP1B1—Melatonin metabolism and effects—FOXO1—muscle cancer	0.000108	0.0132	CbGpPWpGaD
Mitoxantrone—BTK—Kit receptor signaling pathway—KIT—muscle cancer	0.000107	0.0131	CbGpPWpGaD
Mitoxantrone—ABCC1—testis—muscle cancer	0.000105	0.0102	CbGeAlD
Mitoxantrone—ABCG2—bone marrow—muscle cancer	0.000102	0.00983	CbGeAlD
Mitoxantrone—TOP2A—Vinblastine—Vincristine—muscle cancer	0.000101	0.102	CbGdCrCtD
Mitoxantrone—ABCG2—vagina—muscle cancer	9.77e-05	0.00942	CbGeAlD
Mitoxantrone—BTK—B Cell Receptor Signaling Pathway—FOXO1—muscle cancer	9.41e-05	0.0116	CbGpPWpGaD
Mitoxantrone—CYP3A4—renal system—muscle cancer	9.4e-05	0.00906	CbGeAlD
Mitoxantrone—CYP2E1—tendon—muscle cancer	9.12e-05	0.00879	CbGeAlD
Mitoxantrone—ABCC1—S1P1 pathway—PTGS2—muscle cancer	9.03e-05	0.0111	CbGpPWpGaD
Mitoxantrone—ABCB1—embryo—muscle cancer	8.79e-05	0.00847	CbGeAlD
Mitoxantrone—ABCG2—testis—muscle cancer	8.72e-05	0.00841	CbGeAlD
Mitoxantrone—BTK—DAP12 signaling—FOXO4—muscle cancer	8.37e-05	0.0103	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—FOXO4—muscle cancer	7.88e-05	0.00969	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—FOXO4—muscle cancer	7.88e-05	0.00969	CbGpPWpGaD
Mitoxantrone—CYP2E1—head—muscle cancer	7.82e-05	0.00753	CbGeAlD
Mitoxantrone—CYP2E1—testis—muscle cancer	7.55e-05	0.00728	CbGeAlD
Mitoxantrone—Blood uric acid increased—Doxorubicin—muscle cancer	7.37e-05	0.00223	CcSEcCtD
Mitoxantrone—BTK—B Cell Activation—FOXO4—muscle cancer	7.29e-05	0.00897	CbGpPWpGaD
Mitoxantrone—Agranulocytosis—Etoposide—muscle cancer	7.28e-05	0.00221	CcSEcCtD
Mitoxantrone—Back pain—Vincristine—muscle cancer	7.28e-05	0.00221	CcSEcCtD
Mitoxantrone—Sepsis—Methotrexate—muscle cancer	7.25e-05	0.0022	CcSEcCtD
Mitoxantrone—Myalgia—Dactinomycin—muscle cancer	7.17e-05	0.00217	CcSEcCtD
Mitoxantrone—ABCC1—S1P1 pathway—VEGFA—muscle cancer	7.11e-05	0.00875	CbGpPWpGaD
Mitoxantrone—Hyperkalaemia—Doxorubicin—muscle cancer	7.11e-05	0.00216	CcSEcCtD
Mitoxantrone—Discomfort—Dactinomycin—muscle cancer	7.09e-05	0.00215	CcSEcCtD
Mitoxantrone—PIM1—Validated targets of C-MYC transcriptional activation—TP53—muscle cancer	7.09e-05	0.00872	CbGpPWpGaD
Mitoxantrone—TOP2A—Daunorubicin—Doxorubicin—muscle cancer	7.05e-05	0.0718	CbGdCrCtD
Mitoxantrone—TOP2A—Epirubicin—Doxorubicin—muscle cancer	7.05e-05	0.0718	CbGdCrCtD
Mitoxantrone—TOP2A—Idarubicin—Doxorubicin—muscle cancer	7.05e-05	0.0718	CbGdCrCtD
Mitoxantrone—Anaemia—Vincristine—muscle cancer	6.96e-05	0.00211	CcSEcCtD
Mitoxantrone—Oedema—Dactinomycin—muscle cancer	6.88e-05	0.00208	CcSEcCtD
Mitoxantrone—Infection—Dactinomycin—muscle cancer	6.83e-05	0.00207	CcSEcCtD
Mitoxantrone—Blood urea increased—Doxorubicin—muscle cancer	6.83e-05	0.00207	CcSEcCtD
Mitoxantrone—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—muscle cancer	6.76e-05	0.00832	CbGpPWpGaD
Mitoxantrone—Leukopenia—Vincristine—muscle cancer	6.74e-05	0.00204	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Dactinomycin—muscle cancer	6.73e-05	0.00204	CcSEcCtD
Mitoxantrone—ABCB1—renal system—muscle cancer	6.65e-05	0.00641	CbGeAlD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	6.59e-05	0.00811	CbGpPWpGaD
Mitoxantrone—Renal failure acute—Methotrexate—muscle cancer	6.57e-05	0.00199	CcSEcCtD
Mitoxantrone—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—MDM2—muscle cancer	6.56e-05	0.00807	CbGpPWpGaD
Mitoxantrone—Anorexia—Dactinomycin—muscle cancer	6.55e-05	0.00199	CcSEcCtD
Mitoxantrone—Ecchymosis—Doxorubicin—muscle cancer	6.54e-05	0.00198	CcSEcCtD
Mitoxantrone—Convulsion—Vincristine—muscle cancer	6.52e-05	0.00198	CcSEcCtD
Mitoxantrone—Hypertension—Vincristine—muscle cancer	6.5e-05	0.00197	CcSEcCtD
Mitoxantrone—Myalgia—Vincristine—muscle cancer	6.41e-05	0.00194	CcSEcCtD
Mitoxantrone—Chills—Etoposide—muscle cancer	6.28e-05	0.00191	CcSEcCtD
Mitoxantrone—Sepsis—Doxorubicin—muscle cancer	6.28e-05	0.0019	CcSEcCtD
Mitoxantrone—Anaphylactoid reaction—Methotrexate—muscle cancer	6.27e-05	0.0019	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Dactinomycin—muscle cancer	6.26e-05	0.0019	CcSEcCtD
Mitoxantrone—Alopecia—Etoposide—muscle cancer	6.19e-05	0.00188	CcSEcCtD
Mitoxantrone—BTK—DAP12 signaling—FOXO1—muscle cancer	6.18e-05	0.00761	CbGpPWpGaD
Mitoxantrone—Oedema—Vincristine—muscle cancer	6.14e-05	0.00186	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Vincristine—muscle cancer	6.14e-05	0.00186	CcSEcCtD
Mitoxantrone—Infection—Vincristine—muscle cancer	6.1e-05	0.00185	CcSEcCtD
Mitoxantrone—Phlebitis—Doxorubicin—muscle cancer	6.1e-05	0.00185	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Vincristine—muscle cancer	6.01e-05	0.00182	CcSEcCtD
Mitoxantrone—Decreased appetite—Dactinomycin—muscle cancer	5.98e-05	0.00181	CcSEcCtD
Mitoxantrone—Dysgeusia—Etoposide—muscle cancer	5.97e-05	0.00181	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Vincristine—muscle cancer	5.94e-05	0.0018	CcSEcCtD
Mitoxantrone—Fatigue—Dactinomycin—muscle cancer	5.93e-05	0.0018	CcSEcCtD
Mitoxantrone—Back pain—Etoposide—muscle cancer	5.9e-05	0.00179	CcSEcCtD
Mitoxantrone—Pain—Dactinomycin—muscle cancer	5.88e-05	0.00178	CcSEcCtD
Mitoxantrone—Anorexia—Vincristine—muscle cancer	5.86e-05	0.00178	CcSEcCtD
Mitoxantrone—BTK—DAP12 interactions—FOXO1—muscle cancer	5.82e-05	0.00716	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—FOXO1—muscle cancer	5.82e-05	0.00716	CbGpPWpGaD
Mitoxantrone—Cardiac failure congestive—Doxorubicin—muscle cancer	5.79e-05	0.00176	CcSEcCtD
Mitoxantrone—Hypotension—Vincristine—muscle cancer	5.74e-05	0.00174	CcSEcCtD
Mitoxantrone—Renal failure acute—Doxorubicin—muscle cancer	5.69e-05	0.00172	CcSEcCtD
Mitoxantrone—Feeling abnormal—Dactinomycin—muscle cancer	5.67e-05	0.00172	CcSEcCtD
Mitoxantrone—Ill-defined disorder—Etoposide—muscle cancer	5.66e-05	0.00172	CcSEcCtD
Mitoxantrone—Anaemia—Etoposide—muscle cancer	5.64e-05	0.00171	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Dactinomycin—muscle cancer	5.62e-05	0.0017	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Vincristine—muscle cancer	5.6e-05	0.0017	CcSEcCtD
Mitoxantrone—Paraesthesia—Vincristine—muscle cancer	5.52e-05	0.00167	CcSEcCtD
Mitoxantrone—Malaise—Etoposide—muscle cancer	5.5e-05	0.00167	CcSEcCtD
Mitoxantrone—Leukopenia—Etoposide—muscle cancer	5.46e-05	0.00165	CcSEcCtD
Mitoxantrone—Body temperature increased—Dactinomycin—muscle cancer	5.44e-05	0.00165	CcSEcCtD
Mitoxantrone—Abdominal pain—Dactinomycin—muscle cancer	5.44e-05	0.00165	CcSEcCtD
Mitoxantrone—Anaphylactoid reaction—Doxorubicin—muscle cancer	5.43e-05	0.00165	CcSEcCtD
Mitoxantrone—BTK—B Cell Activation—FOXO1—muscle cancer	5.38e-05	0.00662	CbGpPWpGaD
Mitoxantrone—Cardiac failure—Doxorubicin—muscle cancer	5.38e-05	0.00163	CcSEcCtD
Mitoxantrone—Decreased appetite—Vincristine—muscle cancer	5.34e-05	0.00162	CcSEcCtD
Mitoxantrone—Cough—Etoposide—muscle cancer	5.32e-05	0.00161	CcSEcCtD
Mitoxantrone—Fatigue—Vincristine—muscle cancer	5.3e-05	0.00161	CcSEcCtD
Mitoxantrone—Convulsion—Etoposide—muscle cancer	5.28e-05	0.0016	CcSEcCtD
Mitoxantrone—Hyponatraemia—Doxorubicin—muscle cancer	5.27e-05	0.0016	CcSEcCtD
Mitoxantrone—Hypertension—Etoposide—muscle cancer	5.26e-05	0.0016	CcSEcCtD
Mitoxantrone—Constipation—Vincristine—muscle cancer	5.25e-05	0.00159	CcSEcCtD
Mitoxantrone—Pain—Vincristine—muscle cancer	5.25e-05	0.00159	CcSEcCtD
Mitoxantrone—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	5.25e-05	0.00159	CcSEcCtD
Mitoxantrone—TOP2A—Gastric Cancer Network 2—TP53—muscle cancer	5.25e-05	0.00646	CbGpPWpGaD
Mitoxantrone—Chest pain—Etoposide—muscle cancer	5.19e-05	0.00157	CcSEcCtD
Mitoxantrone—Discomfort—Etoposide—muscle cancer	5.13e-05	0.00156	CcSEcCtD
Mitoxantrone—Hypersensitivity—Dactinomycin—muscle cancer	5.07e-05	0.00154	CcSEcCtD
Mitoxantrone—ABCB1—bone marrow—muscle cancer	5.03e-05	0.00485	CbGeAlD
Mitoxantrone—Gastrointestinal pain—Vincristine—muscle cancer	5.02e-05	0.00152	CcSEcCtD
Mitoxantrone—Confusional state—Etoposide—muscle cancer	5.02e-05	0.00152	CcSEcCtD
Mitoxantrone—Pancytopenia—Methotrexate—muscle cancer	4.98e-05	0.00151	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Etoposide—muscle cancer	4.98e-05	0.00151	CcSEcCtD
Mitoxantrone—Infection—Etoposide—muscle cancer	4.94e-05	0.0015	CcSEcCtD
Mitoxantrone—Asthenia—Dactinomycin—muscle cancer	4.93e-05	0.0015	CcSEcCtD
Mitoxantrone—Blood creatinine increased—Doxorubicin—muscle cancer	4.92e-05	0.00149	CcSEcCtD
Mitoxantrone—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	4.91e-05	0.00603	CbGpPWpGaD
Mitoxantrone—Neutropenia—Methotrexate—muscle cancer	4.9e-05	0.00149	CcSEcCtD
Mitoxantrone—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	4.89e-05	0.00602	CbGpPWpGaD
Mitoxantrone—Dehydration—Doxorubicin—muscle cancer	4.88e-05	0.00148	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Etoposide—muscle cancer	4.87e-05	0.00148	CcSEcCtD
Mitoxantrone—Upper respiratory tract infection—Methotrexate—muscle cancer	4.87e-05	0.00148	CcSEcCtD
Mitoxantrone—Tachycardia—Etoposide—muscle cancer	4.86e-05	0.00147	CcSEcCtD
Mitoxantrone—Body temperature increased—Vincristine—muscle cancer	4.86e-05	0.00147	CcSEcCtD
Mitoxantrone—Abdominal pain—Vincristine—muscle cancer	4.86e-05	0.00147	CcSEcCtD
Mitoxantrone—Skin disorder—Etoposide—muscle cancer	4.83e-05	0.00147	CcSEcCtD
Mitoxantrone—Erectile dysfunction—Methotrexate—muscle cancer	4.83e-05	0.00146	CcSEcCtD
Mitoxantrone—ABCB1—vagina—muscle cancer	4.82e-05	0.00465	CbGeAlD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	4.82e-05	0.00593	CbGpPWpGaD
Mitoxantrone—Hyperhidrosis—Etoposide—muscle cancer	4.81e-05	0.00146	CcSEcCtD
Mitoxantrone—Abdominal pain upper—Doxorubicin—muscle cancer	4.8e-05	0.00145	CcSEcCtD
Mitoxantrone—Hypokalaemia—Doxorubicin—muscle cancer	4.78e-05	0.00145	CcSEcCtD
Mitoxantrone—Anorexia—Etoposide—muscle cancer	4.74e-05	0.00144	CcSEcCtD
Mitoxantrone—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	4.73e-05	0.00143	CcSEcCtD
Mitoxantrone—BTK—DAP12 signaling—KIT—muscle cancer	4.71e-05	0.0058	CbGpPWpGaD
Mitoxantrone—Diarrhoea—Dactinomycin—muscle cancer	4.7e-05	0.00143	CcSEcCtD
Mitoxantrone—Pneumonia—Methotrexate—muscle cancer	4.7e-05	0.00143	CcSEcCtD
Mitoxantrone—Drowsiness—Methotrexate—muscle cancer	4.67e-05	0.00142	CcSEcCtD
Mitoxantrone—Hypotension—Etoposide—muscle cancer	4.65e-05	0.00141	CcSEcCtD
Mitoxantrone—Alanine aminotransferase increased—Doxorubicin—muscle cancer	4.63e-05	0.0014	CcSEcCtD
Mitoxantrone—Renal failure—Methotrexate—muscle cancer	4.59e-05	0.00139	CcSEcCtD
Mitoxantrone—Stomatitis—Methotrexate—muscle cancer	4.56e-05	0.00138	CcSEcCtD
Mitoxantrone—Conjunctivitis—Methotrexate—muscle cancer	4.54e-05	0.00138	CcSEcCtD
Mitoxantrone—Hypersensitivity—Vincristine—muscle cancer	4.53e-05	0.00137	CcSEcCtD
Mitoxantrone—Sweating—Methotrexate—muscle cancer	4.48e-05	0.00136	CcSEcCtD
Mitoxantrone—Paraesthesia—Etoposide—muscle cancer	4.47e-05	0.00135	CcSEcCtD
Mitoxantrone—CYP1B1—Tryptophan metabolism—MDM2—muscle cancer	4.47e-05	0.00549	CbGpPWpGaD
Mitoxantrone—Haematuria—Methotrexate—muscle cancer	4.46e-05	0.00135	CcSEcCtD
Mitoxantrone—ABCB1—head—muscle cancer	4.45e-05	0.00429	CbGeAlD
Mitoxantrone—Dyspnoea—Etoposide—muscle cancer	4.44e-05	0.00135	CcSEcCtD
Mitoxantrone—BTK—DAP12 interactions—KIT—muscle cancer	4.43e-05	0.00545	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—KIT—muscle cancer	4.43e-05	0.00545	CbGpPWpGaD
Mitoxantrone—Somnolence—Etoposide—muscle cancer	4.42e-05	0.00134	CcSEcCtD
Mitoxantrone—Asthenia—Vincristine—muscle cancer	4.41e-05	0.00134	CcSEcCtD
Mitoxantrone—Vomiting—Dactinomycin—muscle cancer	4.37e-05	0.00133	CcSEcCtD
Mitoxantrone—Agranulocytosis—Methotrexate—muscle cancer	4.36e-05	0.00132	CcSEcCtD
Mitoxantrone—Rash—Dactinomycin—muscle cancer	4.34e-05	0.00131	CcSEcCtD
Mitoxantrone—Decreased appetite—Etoposide—muscle cancer	4.33e-05	0.00131	CcSEcCtD
Mitoxantrone—BTK—Adaptive Immune System—CD34—muscle cancer	4.32e-05	0.00532	CbGpPWpGaD
Mitoxantrone—Pancytopenia—Doxorubicin—muscle cancer	4.31e-05	0.00131	CcSEcCtD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	4.31e-05	0.0053	CbGpPWpGaD
Mitoxantrone—ABCB1—testis—muscle cancer	4.3e-05	0.00415	CbGeAlD
Mitoxantrone—Fatigue—Etoposide—muscle cancer	4.29e-05	0.0013	CcSEcCtD
Mitoxantrone—Pain—Etoposide—muscle cancer	4.26e-05	0.00129	CcSEcCtD
Mitoxantrone—Constipation—Etoposide—muscle cancer	4.26e-05	0.00129	CcSEcCtD
Mitoxantrone—Neutropenia—Doxorubicin—muscle cancer	4.24e-05	0.00129	CcSEcCtD
Mitoxantrone—Upper respiratory tract infection—Doxorubicin—muscle cancer	4.22e-05	0.00128	CcSEcCtD
Mitoxantrone—Haemoglobin—Methotrexate—muscle cancer	4.22e-05	0.00128	CcSEcCtD
Mitoxantrone—Diarrhoea—Vincristine—muscle cancer	4.2e-05	0.00127	CcSEcCtD
Mitoxantrone—Haemorrhage—Methotrexate—muscle cancer	4.2e-05	0.00127	CcSEcCtD
Mitoxantrone—Hepatitis—Methotrexate—muscle cancer	4.2e-05	0.00127	CcSEcCtD
Mitoxantrone—ABCC1—Arachidonic acid metabolism—PTGS2—muscle cancer	4.16e-05	0.00512	CbGpPWpGaD
Mitoxantrone—Pharyngitis—Methotrexate—muscle cancer	4.16e-05	0.00126	CcSEcCtD
Mitoxantrone—Weight increased—Doxorubicin—muscle cancer	4.13e-05	0.00125	CcSEcCtD
Mitoxantrone—Weight decreased—Doxorubicin—muscle cancer	4.11e-05	0.00125	CcSEcCtD
Mitoxantrone—BTK—B Cell Activation—KIT—muscle cancer	4.1e-05	0.00505	CbGpPWpGaD
Mitoxantrone—Feeling abnormal—Etoposide—muscle cancer	4.1e-05	0.00124	CcSEcCtD
Mitoxantrone—Hyperglycaemia—Doxorubicin—muscle cancer	4.09e-05	0.00124	CcSEcCtD
Mitoxantrone—Nausea—Dactinomycin—muscle cancer	4.08e-05	0.00124	CcSEcCtD
Mitoxantrone—Pneumonia—Doxorubicin—muscle cancer	4.07e-05	0.00123	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Etoposide—muscle cancer	4.07e-05	0.00123	CcSEcCtD
Mitoxantrone—Drowsiness—Doxorubicin—muscle cancer	4.05e-05	0.00123	CcSEcCtD
Mitoxantrone—CYP1B1—Arachidonic acid metabolism—PTGS2—muscle cancer	4.03e-05	0.00496	CbGpPWpGaD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—MDM2—muscle cancer	4.01e-05	0.00493	CbGpPWpGaD
Mitoxantrone—Renal failure—Doxorubicin—muscle cancer	3.98e-05	0.00121	CcSEcCtD
Mitoxantrone—Urticaria—Etoposide—muscle cancer	3.95e-05	0.0012	CcSEcCtD
Mitoxantrone—Stomatitis—Doxorubicin—muscle cancer	3.94e-05	0.0012	CcSEcCtD
Mitoxantrone—Jaundice—Doxorubicin—muscle cancer	3.94e-05	0.0012	CcSEcCtD
Mitoxantrone—Abdominal pain—Etoposide—muscle cancer	3.93e-05	0.00119	CcSEcCtD
Mitoxantrone—Body temperature increased—Etoposide—muscle cancer	3.93e-05	0.00119	CcSEcCtD
Mitoxantrone—Conjunctivitis—Doxorubicin—muscle cancer	3.93e-05	0.00119	CcSEcCtD
Mitoxantrone—Urinary tract infection—Doxorubicin—muscle cancer	3.93e-05	0.00119	CcSEcCtD
Mitoxantrone—ABCG2—HIF-2-alpha transcription factor network—VEGFA—muscle cancer	3.93e-05	0.00483	CbGpPWpGaD
Mitoxantrone—Vomiting—Vincristine—muscle cancer	3.91e-05	0.00118	CcSEcCtD
Mitoxantrone—Sweating—Doxorubicin—muscle cancer	3.88e-05	0.00118	CcSEcCtD
Mitoxantrone—Rash—Vincristine—muscle cancer	3.87e-05	0.00117	CcSEcCtD
Mitoxantrone—Dermatitis—Vincristine—muscle cancer	3.87e-05	0.00117	CcSEcCtD
Mitoxantrone—Haematuria—Doxorubicin—muscle cancer	3.86e-05	0.00117	CcSEcCtD
Mitoxantrone—Headache—Vincristine—muscle cancer	3.85e-05	0.00117	CcSEcCtD
Mitoxantrone—Sinusitis—Doxorubicin—muscle cancer	3.8e-05	0.00115	CcSEcCtD
Mitoxantrone—Agranulocytosis—Doxorubicin—muscle cancer	3.78e-05	0.00115	CcSEcCtD
Mitoxantrone—Chills—Methotrexate—muscle cancer	3.76e-05	0.00114	CcSEcCtD
Mitoxantrone—BTK—DAP12 signaling—MDM2—muscle cancer	3.71e-05	0.00457	CbGpPWpGaD
Mitoxantrone—Alopecia—Methotrexate—muscle cancer	3.71e-05	0.00112	CcSEcCtD
Mitoxantrone—Bradycardia—Doxorubicin—muscle cancer	3.7e-05	0.00112	CcSEcCtD
Mitoxantrone—Hypersensitivity—Etoposide—muscle cancer	3.67e-05	0.00111	CcSEcCtD
Mitoxantrone—Erythema—Methotrexate—muscle cancer	3.65e-05	0.00111	CcSEcCtD
Mitoxantrone—Haemoglobin—Doxorubicin—muscle cancer	3.65e-05	0.00111	CcSEcCtD
Mitoxantrone—Nausea—Vincristine—muscle cancer	3.65e-05	0.00111	CcSEcCtD
Mitoxantrone—Rhinitis—Doxorubicin—muscle cancer	3.64e-05	0.0011	CcSEcCtD
Mitoxantrone—Haemorrhage—Doxorubicin—muscle cancer	3.63e-05	0.0011	CcSEcCtD
Mitoxantrone—Hepatitis—Doxorubicin—muscle cancer	3.63e-05	0.0011	CcSEcCtD
Mitoxantrone—Pharyngitis—Doxorubicin—muscle cancer	3.61e-05	0.00109	CcSEcCtD
Mitoxantrone—Dysgeusia—Methotrexate—muscle cancer	3.58e-05	0.00108	CcSEcCtD
Mitoxantrone—Asthenia—Etoposide—muscle cancer	3.57e-05	0.00108	CcSEcCtD
Mitoxantrone—Back pain—Methotrexate—muscle cancer	3.53e-05	0.00107	CcSEcCtD
Mitoxantrone—BTK—DAP12 interactions—MDM2—muscle cancer	3.49e-05	0.0043	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	3.49e-05	0.0043	CbGpPWpGaD
Mitoxantrone—Vision blurred—Methotrexate—muscle cancer	3.44e-05	0.00104	CcSEcCtD
Mitoxantrone—Diarrhoea—Etoposide—muscle cancer	3.4e-05	0.00103	CcSEcCtD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	3.39e-05	0.00417	CbGpPWpGaD
Mitoxantrone—Ill-defined disorder—Methotrexate—muscle cancer	3.39e-05	0.00103	CcSEcCtD
Mitoxantrone—Anaemia—Methotrexate—muscle cancer	3.38e-05	0.00102	CcSEcCtD
Mitoxantrone—Malaise—Methotrexate—muscle cancer	3.29e-05	0.000999	CcSEcCtD
Mitoxantrone—Leukopenia—Methotrexate—muscle cancer	3.27e-05	0.000991	CcSEcCtD
Mitoxantrone—Chills—Doxorubicin—muscle cancer	3.26e-05	0.000988	CcSEcCtD
Mitoxantrone—Arrhythmia—Doxorubicin—muscle cancer	3.25e-05	0.000984	CcSEcCtD
Mitoxantrone—BTK—B Cell Activation—MDM2—muscle cancer	3.23e-05	0.00398	CbGpPWpGaD
Mitoxantrone—Alopecia—Doxorubicin—muscle cancer	3.21e-05	0.000973	CcSEcCtD
Mitoxantrone—Cough—Methotrexate—muscle cancer	3.19e-05	0.000966	CcSEcCtD
Mitoxantrone—Convulsion—Methotrexate—muscle cancer	3.16e-05	0.00096	CcSEcCtD
Mitoxantrone—Vomiting—Etoposide—muscle cancer	3.16e-05	0.000959	CcSEcCtD
Mitoxantrone—Erythema—Doxorubicin—muscle cancer	3.16e-05	0.000959	CcSEcCtD
Mitoxantrone—Rash—Etoposide—muscle cancer	3.14e-05	0.000951	CcSEcCtD
Mitoxantrone—Dermatitis—Etoposide—muscle cancer	3.13e-05	0.000951	CcSEcCtD
Mitoxantrone—Headache—Etoposide—muscle cancer	3.12e-05	0.000945	CcSEcCtD
Mitoxantrone—Arthralgia—Methotrexate—muscle cancer	3.11e-05	0.000943	CcSEcCtD
Mitoxantrone—Chest pain—Methotrexate—muscle cancer	3.11e-05	0.000943	CcSEcCtD
Mitoxantrone—Myalgia—Methotrexate—muscle cancer	3.11e-05	0.000943	CcSEcCtD
Mitoxantrone—Dysgeusia—Doxorubicin—muscle cancer	3.1e-05	0.000939	CcSEcCtD
Mitoxantrone—Discomfort—Methotrexate—muscle cancer	3.07e-05	0.000932	CcSEcCtD
Mitoxantrone—BTK—Innate Immune System—FOXO4—muscle cancer	3.06e-05	0.00377	CbGpPWpGaD
Mitoxantrone—Back pain—Doxorubicin—muscle cancer	3.06e-05	0.000928	CcSEcCtD
Mitoxantrone—ABCG2—Fluoropyrimidine Activity—TP53—muscle cancer	3.04e-05	0.00374	CbGpPWpGaD
Mitoxantrone—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	3.02e-05	0.00371	CbGpPWpGaD
Mitoxantrone—Confusional state—Methotrexate—muscle cancer	3.01e-05	0.000911	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Methotrexate—muscle cancer	2.98e-05	0.000904	CcSEcCtD
Mitoxantrone—Vision blurred—Doxorubicin—muscle cancer	2.98e-05	0.000904	CcSEcCtD
Mitoxantrone—Infection—Methotrexate—muscle cancer	2.96e-05	0.000898	CcSEcCtD
Mitoxantrone—Nausea—Etoposide—muscle cancer	2.96e-05	0.000896	CcSEcCtD
Mitoxantrone—BTK—Adaptive Immune System—FOXO4—muscle cancer	2.94e-05	0.00362	CbGpPWpGaD
Mitoxantrone—Ill-defined disorder—Doxorubicin—muscle cancer	2.93e-05	0.00089	CcSEcCtD
Mitoxantrone—Anaemia—Doxorubicin—muscle cancer	2.92e-05	0.000886	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Methotrexate—muscle cancer	2.92e-05	0.000885	CcSEcCtD
Mitoxantrone—CYP2E1—Tryptophan metabolism—MDM2—muscle cancer	2.92e-05	0.00359	CbGpPWpGaD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—CDKN2A—muscle cancer	2.91e-05	0.00358	CbGpPWpGaD
Mitoxantrone—Skin disorder—Methotrexate—muscle cancer	2.9e-05	0.000878	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Methotrexate—muscle cancer	2.88e-05	0.000874	CcSEcCtD
Mitoxantrone—Malaise—Doxorubicin—muscle cancer	2.85e-05	0.000865	CcSEcCtD
Mitoxantrone—Anorexia—Methotrexate—muscle cancer	2.84e-05	0.000862	CcSEcCtD
Mitoxantrone—Leukopenia—Doxorubicin—muscle cancer	2.83e-05	0.000858	CcSEcCtD
Mitoxantrone—Hypotension—Methotrexate—muscle cancer	2.79e-05	0.000845	CcSEcCtD
Mitoxantrone—Cough—Doxorubicin—muscle cancer	2.76e-05	0.000837	CcSEcCtD
Mitoxantrone—Convulsion—Doxorubicin—muscle cancer	2.74e-05	0.000831	CcSEcCtD
Mitoxantrone—Hypertension—Doxorubicin—muscle cancer	2.73e-05	0.000828	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Methotrexate—muscle cancer	2.72e-05	0.000823	CcSEcCtD
Mitoxantrone—Myalgia—Doxorubicin—muscle cancer	2.69e-05	0.000816	CcSEcCtD
Mitoxantrone—Arthralgia—Doxorubicin—muscle cancer	2.69e-05	0.000816	CcSEcCtD
Mitoxantrone—Chest pain—Doxorubicin—muscle cancer	2.69e-05	0.000816	CcSEcCtD
Mitoxantrone—Anxiety—Doxorubicin—muscle cancer	2.68e-05	0.000814	CcSEcCtD
Mitoxantrone—Paraesthesia—Methotrexate—muscle cancer	2.68e-05	0.000812	CcSEcCtD
Mitoxantrone—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—muscle cancer	2.67e-05	0.00329	CbGpPWpGaD
Mitoxantrone—Discomfort—Doxorubicin—muscle cancer	2.66e-05	0.000807	CcSEcCtD
Mitoxantrone—Dyspnoea—Methotrexate—muscle cancer	2.66e-05	0.000806	CcSEcCtD
Mitoxantrone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	2.65e-05	0.00326	CbGpPWpGaD
Mitoxantrone—Somnolence—Methotrexate—muscle cancer	2.65e-05	0.000803	CcSEcCtD
Mitoxantrone—Dyspepsia—Methotrexate—muscle cancer	2.62e-05	0.000796	CcSEcCtD
Mitoxantrone—BTK—Immune System—CD34—muscle cancer	2.62e-05	0.00323	CbGpPWpGaD
Mitoxantrone—Confusional state—Doxorubicin—muscle cancer	2.6e-05	0.000789	CcSEcCtD
Mitoxantrone—Decreased appetite—Methotrexate—muscle cancer	2.59e-05	0.000786	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Doxorubicin—muscle cancer	2.58e-05	0.000783	CcSEcCtD
Mitoxantrone—Oedema—Doxorubicin—muscle cancer	2.58e-05	0.000783	CcSEcCtD
Mitoxantrone—Fatigue—Methotrexate—muscle cancer	2.57e-05	0.000779	CcSEcCtD
Mitoxantrone—Infection—Doxorubicin—muscle cancer	2.56e-05	0.000778	CcSEcCtD
Mitoxantrone—Pain—Methotrexate—muscle cancer	2.55e-05	0.000773	CcSEcCtD
Mitoxantrone—Shock—Doxorubicin—muscle cancer	2.54e-05	0.00077	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Doxorubicin—muscle cancer	2.53e-05	0.000766	CcSEcCtD
Mitoxantrone—Tachycardia—Doxorubicin—muscle cancer	2.52e-05	0.000764	CcSEcCtD
Mitoxantrone—Skin disorder—Doxorubicin—muscle cancer	2.51e-05	0.00076	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Doxorubicin—muscle cancer	2.5e-05	0.000757	CcSEcCtD
Mitoxantrone—Anorexia—Doxorubicin—muscle cancer	2.46e-05	0.000746	CcSEcCtD
Mitoxantrone—Feeling abnormal—Methotrexate—muscle cancer	2.46e-05	0.000745	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Methotrexate—muscle cancer	2.44e-05	0.000739	CcSEcCtD
Mitoxantrone—Hypotension—Doxorubicin—muscle cancer	2.41e-05	0.000731	CcSEcCtD
Mitoxantrone—Urticaria—Methotrexate—muscle cancer	2.37e-05	0.000718	CcSEcCtD
Mitoxantrone—Body temperature increased—Methotrexate—muscle cancer	2.36e-05	0.000714	CcSEcCtD
Mitoxantrone—Abdominal pain—Methotrexate—muscle cancer	2.36e-05	0.000714	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Doxorubicin—muscle cancer	2.35e-05	0.000713	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—BUB1B—muscle cancer	2.33e-05	0.00287	CbGpPWpGaD
Mitoxantrone—Paraesthesia—Doxorubicin—muscle cancer	2.32e-05	0.000703	CcSEcCtD
Mitoxantrone—ABCG2—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	2.31e-05	0.00284	CbGpPWpGaD
Mitoxantrone—Dyspnoea—Doxorubicin—muscle cancer	2.3e-05	0.000698	CcSEcCtD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—TP53—muscle cancer	2.3e-05	0.00283	CbGpPWpGaD
Mitoxantrone—Somnolence—Doxorubicin—muscle cancer	2.29e-05	0.000696	CcSEcCtD
Mitoxantrone—Dyspepsia—Doxorubicin—muscle cancer	2.27e-05	0.000689	CcSEcCtD
Mitoxantrone—BTK—Innate Immune System—FOXO1—muscle cancer	2.26e-05	0.00278	CbGpPWpGaD
Mitoxantrone—Decreased appetite—Doxorubicin—muscle cancer	2.24e-05	0.00068	CcSEcCtD
Mitoxantrone—Fatigue—Doxorubicin—muscle cancer	2.23e-05	0.000675	CcSEcCtD
Mitoxantrone—Pain—Doxorubicin—muscle cancer	2.21e-05	0.000669	CcSEcCtD
Mitoxantrone—Constipation—Doxorubicin—muscle cancer	2.21e-05	0.000669	CcSEcCtD
Mitoxantrone—Hypersensitivity—Methotrexate—muscle cancer	2.2e-05	0.000666	CcSEcCtD
Mitoxantrone—BTK—Adaptive Immune System—FOXO1—muscle cancer	2.17e-05	0.00267	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	2.17e-05	0.00267	CbGpPWpGaD
Mitoxantrone—Asthenia—Methotrexate—muscle cancer	2.14e-05	0.000648	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	2.14e-05	0.00263	CbGpPWpGaD
Mitoxantrone—Feeling abnormal—Doxorubicin—muscle cancer	2.13e-05	0.000645	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Doxorubicin—muscle cancer	2.11e-05	0.00064	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle—BUB1B—muscle cancer	2.09e-05	0.00257	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	2.06e-05	0.00253	CbGpPWpGaD
Mitoxantrone—Urticaria—Doxorubicin—muscle cancer	2.05e-05	0.000622	CcSEcCtD
Mitoxantrone—Body temperature increased—Doxorubicin—muscle cancer	2.04e-05	0.000619	CcSEcCtD
Mitoxantrone—Abdominal pain—Doxorubicin—muscle cancer	2.04e-05	0.000619	CcSEcCtD
Mitoxantrone—Diarrhoea—Methotrexate—muscle cancer	2.04e-05	0.000618	CcSEcCtD
Mitoxantrone—Hypersensitivity—Doxorubicin—muscle cancer	1.9e-05	0.000577	CcSEcCtD
Mitoxantrone—Vomiting—Methotrexate—muscle cancer	1.9e-05	0.000575	CcSEcCtD
Mitoxantrone—Rash—Methotrexate—muscle cancer	1.88e-05	0.00057	CcSEcCtD
Mitoxantrone—Dermatitis—Methotrexate—muscle cancer	1.88e-05	0.000569	CcSEcCtD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.87e-05	0.00231	CbGpPWpGaD
Mitoxantrone—Headache—Methotrexate—muscle cancer	1.87e-05	0.000566	CcSEcCtD
Mitoxantrone—Asthenia—Doxorubicin—muscle cancer	1.85e-05	0.000562	CcSEcCtD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.81e-05	0.00223	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—FOXO4—muscle cancer	1.78e-05	0.00219	CbGpPWpGaD
Mitoxantrone—Nausea—Methotrexate—muscle cancer	1.77e-05	0.000537	CcSEcCtD
Mitoxantrone—Diarrhoea—Doxorubicin—muscle cancer	1.77e-05	0.000535	CcSEcCtD
Mitoxantrone—BTK—Innate Immune System—KIT—muscle cancer	1.72e-05	0.00212	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—KIT—muscle cancer	1.65e-05	0.00203	CbGpPWpGaD
Mitoxantrone—Vomiting—Doxorubicin—muscle cancer	1.64e-05	0.000498	CcSEcCtD
Mitoxantrone—Rash—Doxorubicin—muscle cancer	1.63e-05	0.000493	CcSEcCtD
Mitoxantrone—Dermatitis—Doxorubicin—muscle cancer	1.63e-05	0.000493	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	1.62e-05	0.002	CbGpPWpGaD
Mitoxantrone—Headache—Doxorubicin—muscle cancer	1.62e-05	0.00049	CcSEcCtD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	1.59e-05	0.00195	CbGpPWpGaD
Mitoxantrone—Nausea—Doxorubicin—muscle cancer	1.53e-05	0.000465	CcSEcCtD
Mitoxantrone—ABCC1—Metabolism—FH—muscle cancer	1.48e-05	0.00182	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—FH—muscle cancer	1.43e-05	0.00176	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—MDM2—muscle cancer	1.36e-05	0.00167	CbGpPWpGaD
Mitoxantrone—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	1.35e-05	0.00167	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—FOXO1—muscle cancer	1.32e-05	0.00162	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—MDM2—muscle cancer	1.3e-05	0.0016	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—FH—muscle cancer	1.3e-05	0.0016	CbGpPWpGaD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	1.25e-05	0.00154	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	1.23e-05	0.00151	CbGpPWpGaD
Mitoxantrone—TOP2A—Circadian rythm related genes—TP53—muscle cancer	1.18e-05	0.00145	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—VEGFA—muscle cancer	1.08e-05	0.00133	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—CDKN2A—muscle cancer	1.07e-05	0.00131	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—KIT—muscle cancer	1e-05	0.00123	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—CDKN2A—muscle cancer	9.53e-06	0.00117	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—FH—muscle cancer	9.33e-06	0.00115	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—MDM2—muscle cancer	9.25e-06	0.00114	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—ENO2—muscle cancer	9.09e-06	0.00112	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—MED12—muscle cancer	8.35e-06	0.00103	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—HMGA1—muscle cancer	8.26e-06	0.00102	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—MED12—muscle cancer	8.07e-06	0.000993	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—MDM2—muscle cancer	7.9e-06	0.000972	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—ENO2—muscle cancer	7.61e-06	0.000936	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—FOXO4—muscle cancer	7.41e-06	0.000911	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—ENO2—muscle cancer	7.36e-06	0.000906	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—MED12—muscle cancer	7.34e-06	0.000904	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	7.03e-06	0.000865	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—FH—muscle cancer	7.03e-06	0.000865	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	6.78e-06	0.000834	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—ENO2—muscle cancer	6.7e-06	0.000824	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	5.95e-06	0.000732	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	5.76e-06	0.000708	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—FOXO1—muscle cancer	5.47e-06	0.000673	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	5.34e-06	0.000657	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—TP53—muscle cancer	5.31e-06	0.000653	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—MED12—muscle cancer	5.27e-06	0.000649	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—ENO2—muscle cancer	4.81e-06	0.000592	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—FH—muscle cancer	4.33e-06	0.000533	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—KIT—muscle cancer	4.17e-06	0.000513	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	4.04e-06	0.000497	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—MED12—muscle cancer	3.97e-06	0.000489	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—ENO2—muscle cancer	3.62e-06	0.000445	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—MDM2—muscle cancer	3.28e-06	0.000404	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—PTGS2—muscle cancer	3.16e-06	0.000389	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—PTGS2—muscle cancer	2.65e-06	0.000326	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—PTGS2—muscle cancer	2.56e-06	0.000315	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—MED12—muscle cancer	2.45e-06	0.000301	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—PTGS2—muscle cancer	2.33e-06	0.000287	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—ENO2—muscle cancer	2.23e-06	0.000274	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—PTGS2—muscle cancer	1.67e-06	0.000206	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—PTGS2—muscle cancer	1.26e-06	0.000155	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—PTGS2—muscle cancer	7.77e-07	9.56e-05	CbGpPWpGaD
